Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Entropy Technologies LP

Entropy Technologies LP decreased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 60.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,620 shares of the biotechnology company’s stock after selling 16,519 shares during the quarter. Entropy Technologies LP’s holdings in Arrowhead Pharmaceuticals were worth $666,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Tsfg LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $25,000. First Horizon Corp purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $32,000. WPG Advisers LLC increased its stake in Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after buying an additional 431 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 471 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ARWR shares. Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings cut shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. JPMorgan Chase & Co. increased their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Finally, Chardan Capital raised their price target on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.08.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the transaction, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $86.22 on Thursday. The stock’s fifty day moving average is $78.61 and its two-hundred day moving average is $70.41. The firm has a market capitalization of $12.14 billion, a P/E ratio of -40.10 and a beta of 1.26. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $15.01 and a fifty-two week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. During the same period last year, the company earned $2.75 EPS. The company’s revenue for the quarter was down 86.4% on a year-over-year basis. On average, research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.08 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.